Background and Aims: Chronic cannabis use is associated with nausea and vomiting that may lead to emergency department (ED) visits, multiple diagnostic tests, and procedures. The aim of this study was to analyze recent trends in ED visits for vomiting associated with cannabis use disorder between 2006 and 2013.
C
annabis is the most widely accessible and consumed illicit drug worldwide. 1 The number of daily cannabis users in the United States increased from 5.1 million in 2005 to 8.1 million individuals in 2013. In that same year there was an estimated 19.8 million previous month users. 2 The most common age group to use marijuana comprises individuals between 18 to 25 years of age. 3 The vast majority of individuals use cannabis recreationally, however, at prescribed doses cannabis has been reported to help patients suffering from cachexia, cancer, glaucoma, human immunodeficiency virus infection/acquired immune deficiency syndrome, and pain among other conditions. 4 For these reasons, as of July 2016 cannabis is now legal in 25 states and the District of Columbia for medicinal purposes and is legal for recreational purposes in 4 states. 5, 6 The Food and Drug Administration had approved 2 cannabinoids in the United States for cancer chemotherapy-induced nausea and vomiting and for patients with human immunodeficiency virus or cancer as an appetite stimulant. 7, 8 There is increasing evidence of potential adverse side effects of chronic cannabis use. In a recent single center study conducted on patients in a tertiary care hospital gastroenterology clinic, there was a 1.47-fold increase in emergency department (ED) visits per year for gastrointestinal patients with cannabis dependence compared with noncannabis abusers. 9 Likewise, after the liberalization of medicinal cannabis in Colorado in 2009, the ED visits for cyclic vomiting at 2 medical centers increased from ∼36/ 100,000 ED to 70/100,000 ED visits. 10 In addition, patients may present to the ED with nonspecific symptoms that are triggered by cannabis use, including anxiety and panic attacks. 11 Cannabinoid hyperemesis syndrome (CHS), was first well-described in 2004 by Allen et al, 12 by observing 19 patients with chronic cannabis use suffering from cyclical vomiting occurring every few weeks or months, with improvement in symptoms following cessation of cannabis use. Three patients rechallenged themselves with marijuana and relapsed within months. Since then, multiple reports have been published and the disorder has been increasingly recognized. [13] [14] [15] [16] [17] [18] [19] [20] [21] However, the true prevalence of this disorder is unknown. Risk factors for CHS, other than cannabis use are also not known. A study with 98 patients reported that the majority of patients became symptomatic within 1 to 5 years of the beginning of daily cannabis use. Moreover, 32% of patients developed symptoms within the first year of cannabis use. 20 Discontinuation of cannabis use may relieve CHS symptoms, 12 although in general studies are lacking adequate follow-up. 16, 20, 22 Recently, the Rome IV Criteria defined CHS as the presence of all of the following symptoms: (i) stereotypical episodic vomiting similar to cyclic vomiting syndrome in regards to onset, duration, and frequency; (ii) symptomatic after chronic cannabis use; (iii) relief of episodes upon cessation of cannabis use. 23 These symptoms should be fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis. The observation that prolonged hot baths or showers provides temporary relief of symptoms also supports the diagnosis. Patients with CHS sometimes also experience epigastric or periumbilical abdominal discomfort or pain. 16 The purpose of this study was to analyze the national trends in the rates of ED visits for nausea and vomiting associated with cannabis use disorder in the United States. No previous study has evaluated nausea and vomiting prevalence in the presence of cannabis use disorder in the ED on a nationwide scale from 2006 to 2013.
METHODS
This study extracted data from the Nationwide Emergency Department Sample (NEDS) 24 from the Healthcare Utilization Project (HCUP), 25 The DSM-IV-TR had separate diagnoses for cannabis abuse and cannabis dependence, but combines them into one disorder in DSM-V, cannabis use disorder, which we will refer to in this paper. 26 Cannabis use disorder is defined as a consequential trend of cannabis use that results in at least 2 of the following symptoms: (i) cannabis use for a long period of time; (ii) unsuccessful attempts to limit cannabis use; (iii) a significant amount of time dedicated to activities related to cannabis use; (iv) craving cannabis; (v) cannabis use resulting in negligence towards responsibilities; (vi) continued cannabis use after experiencing the negative effects of cannabis; (vii) activities are limited due to cannabis use; (viii) cannabis use in perilous environments; (ix) cannabis use even after experiencing cannabis related side-effects; (x) tolerance; and (xi) withdrawal. 26 Despite extensive criteria for diagnosis, previous research has shown that this disorder is as accurately diagnosed as other drug use disorders. 27 
Study Variables
We included patients with a primary diagnosis of vomiting alone, persistent vomiting or nausea with vomiting as defined by HCUPnet as the first-listed diagnosis on a medical record. This was determined to be the principal reason for the ED visit. Out of the patients with a primary diagnosis of vomiting, we analyzed how many also had cannabis abuse (305.2×) or cannabis dependence (304.3×) coded during their ED visit as well as one of their other 14 listed diagnoses. We used STATA/MP 14.1 to analyze patient statistics including age, sex, primary payer, residence [large, medium, or small metropolitan, large fringe (suburb) or micropolitan], and median income for zip-code (low or not low). Hospital characteristics were also obtained from using STATA/MP 14.1 and HCUPnet and included region (Northeast, Midwest, South, or West), location (metropolitan or nonmetropolitan), trauma center designation, and teaching status. We used STATA/MP 14.1 to analyze the 2006 and 2013 NEDS datasets for associated costs, inpatient admission information, and other diagnoses. 25 The variables included in this study are defined according to HCUPnet. Demographic data by zip code collected by Claritas defined the median income of a patient's zip code. The lowest income quartile ranged from $1 to $37,999 (low), while the 3 highest income quartiles were defined as $38,000 and above (not low). A "large central" residence specifies metro areas considered cores of large cities with a population of 1 million or more. A "large fringe" residence specifies suburbs of large cities with a population of 1 million or more. "Medium and small metro" residences specifies metro areas that have a population <1 million but > 50,000. "Micropolitan and noncore" residences refer to rural counties that have a population below 50,000. The American Hospital Association (AHA) Annual Survey determines teaching hospital status if a hospital has an AMA-approved residency program, Council of Teaching Hospitals (COTH) membership, or 0.25 or higher ratio of residents and full-time equivalent interns to beds. American Hospital Association (AHA) Annual Survey of Hospitals determines hospital ownership.
Statistical Analysis
The rate of vomiting and cannabis ED visits per 100,000 ED visits in 2006 was calculated for all patient and hospital characteristics by dividing the number of vomiting and cannabis ED visits in each category by the total number of ED visits within that respective category, then multiplying by 100,000. For example, the rate of vomiting and cannabis ED visits per 100,000 ED visits for the 20 to 29 age group in 2006 was calculated by dividing the number of vomiting and cannabis ED visits in the 20 to 29 age group (1147) by the total number of ED visits for the 20 to 29 age group (18, 226, 784) , then multiplying by 100,000. The rate of vomiting with cannabis ED visits per 100,000 residents in 2006 was calculated with age group populations taken from US Census divided by the number of vomiting with cannabis ED visits in each category by the total number of the respective age group's population, then multiplying by 100,000.
The cost data for 2006 and 2013 were calculated from the source files of the respective NEDS databases using STATA/MP14.1. Individual payer costs were calculated from the percentage of total vomiting and cannabis ED visits paid by each payer, multiplied by the aggregate cost of vomiting and cannabis ED visits in 2013. All costs were adjusted for inflation and reported in terms of 2015 dollars using the Consumer Price Index inflation calculator. 28 vomiting without cannabis use increased from 1141 in 2006 to 1435 in 2013, a 24.9% increase.
Costs
The 
Demographics

Age
The 20 to 29 year age group had the highest rate of ED visits for vomiting with cannabis use disorder per 100,000 ED visits with 6.8/100,000 in 2006 and 39.0/100,000 in 2013 (Fig. 2) . The lowest rate of ED visits per 100,000 ED visits for vomiting with cannabis use disorder, but the greatest increase between the years, was the 30 to 39 year old age group with 4.0/100,000 in 2006 and 23.4/100,000 in 2013 (Fig. 2) . All of the age groups displayed increases in rates of ED visits for nausea and vomiting with cannabis use disorder.
Gender
Men presented to the ED for vomiting with cannabis use disorder at a higher rate than women in both 2006 and 2013 (Fig. 3) . The rate of ED visits for men in 2006 was 3.0/ 100,000 ED visits and it increased to 16.8/100,000 ED visits in 2013. The rate of ED visits for women increased in line with that of men from 1.9/100,000 ED visits in 2006 to 10.3/ 100,000 ED visits in 2013.
Geographical Region
In 2006, the Midwest had the highest rates of ED visits for vomiting with cannabis use disorder (3.1/100,000 ED visits) and the North had the lowest rates (1.5/100,000 ED visits). However, in 2013 patients in the West had the highest rates of ED visits for vomiting with cannabis use disorder in 2013 (22.8/100,000 ED visits) and the Northeast had the lowest rates (8.7/100,000 ED visits). The greatest increase between 2006 and 2013 was in the West.
The patients living in the "Large Fringe Metro (suburbs)" had the highest increase in ED visit rates for vomiting and cannabis use disorder (Table 1 ). For the "suburbs" the rates increased from 1.6/100,000 to 11.8/100,000 for 2006 and 2013. "Medium and small metro" had the lowest rates of increase rising from 3.1/100,000 to 11. therefore patients may be more likely to report its use. Likewise, there is also increasing awareness about the association between chronic cannabis use and recurrent vomiting and therefore physicians may be more likely to ask patients about cannabis use. It is also possible that the rise in ED visits related to cannabis use may potentially be contributed by the increase in delta-9-tetrahydrocannabinol (THC) potency, which has increased from 1% to 5% in the late 1960s to as high as 10% to 15% at present. 26 In addition, the number of individuals in the United States using cannabis has increased 29 along with the types and quantities. 11 Finally, it is possible that the increase is confounded with increasing rates of opioid use given its association with nausea and vomiting. 30 The mechanism whereby chronic cannabis use results in severe vomiting remains unclear. The active ingredient in cannabis, THC, binds to cannabinoid receptors 1 and 2 (CB1 and CB2), which affect the nervous system, enteric plexus, and the body's immune system. It has been reported that cannabis slows gastric emptying, which may promote nausea and vomiting. 12, 16, 20, 31 In addition, it is also believed that the buildup of lipophilic THC in cerebral fat may manifest itself as toxic in some individuals which can promote vomiting. 32 Also, genetic variations in hepatic drug transforming enzymes in susceptible individuals may cause high levels of cannabis metabolites thereby promoting the development of vomiting. 16 The findings of this study do not exclude potential antiemetic benefits of cannabis or that many of the patients were using cannabis to treat their nausea and vomiting. THC has been shown to selectively act on CB1 receptors in dorsal vagal complex to inhibit emesis. 33 An internet survey of patients with cyclic vomiting syndrome found that nearly half of the patients who used cannabis reported improvement in nausea, appetite, general well-being, stress and vomiting. 34 A recent meta-analysis that included 3 trials found cannabinoids to be associated with improvement in nausea and vomiting due to chemotherapy though the evidence was low-quality. 35 Thus, at present the role of cannabis for the management of chronic nausea and vomiting remains controversial particularly in light of the potential of cannabis to affect other brain functions and cause side effects. 36 This study has several limitations. First, this study relies on ICD-9 billing codes which may not always be accurate. CHS is not well recognized by many ED physicians and therefore even the 2013 rates may not accurately represent the number of ED visits and therefore likely grossly underestimate the true problem. There may be a lack of identification of associated symptoms such as abdominal pain. Second, a causal relationship cannot be definitely established between cannabis use disorder and vomiting. In 2006, when there was a primary diagnosis of vomiting the most common secondary diagnoses were: tobacco use disorder, diarrhea, dehydration, cocaine abuse, hypertension, potassium deficiency, alcohol abuse, abdominal pain, esophageal reflux, and epigastric pain. In 2013, the most common secondary diagnoses were: tobacco use disorder, abdominal pain, hypertension, diarrhea, potassium deficiency, anxiety, dehydration, esophageal reflux, major depressive disorder, and asthma. Third, though the NEDS provides a representation of the US population it only collected information from 24 states in 2006 and 30 states in 2013. As demonstrated by differences in the laws regarding medical marijuana and even the legalization of marijuana, states differ with regard to acceptance and stigma of marijuana use. Therefore there are likely to be differences among the states in the awareness of the association between cannabis and vomiting and the likelihood of patients to accurately report cannabis use disorder.
CONCLUSIONS
This study found a significant number of patients presenting to the ED with nausea and vomiting in the presence of cannabis use disorder, as well as the huge cost burden associated with these ED visits. Further research is needed to diagnose patients presenting to the ED with CHS and formulate a standardized regimen of treatment. Furthermore, research is needed about the dosing and potency of cannabis, as well as safety practices for patients and providers.
